Vaccinations against various types of cancer and drug boosters that are suitable for reducing the effective doses of drugs - this is what Defence Therapeutics stood for, until yesterday. Now the Company has expanded its portfolio: the active ingredient AccuTOX ensures that cancer cells die. A Phase 1 trial is planned for 2023. Find out what the new application means and how the Company is otherwise positioned in our update.Den vollständigen Artikel lesen ...
© 2022 researchanalyst.com (EN)